

Disclaimer

This presentation has been prepared by LifeHealthcare Group Limited ("LifeHealthcare") on the basis of information available to LifeHealthcare as at October 2013 and is given to recipients in confidence. No part of this presentation may be circulated, reproduced or provided to any third party, and the matters referred to in it must not be disclosed to third parties, in whole or in part.

This presentation is intended to provide a general outline of matters of interest only and is not intended to be a definitive statement or advice on the subject matter. This presentation is not legal, tax, accounting or financial product advice and has been prepared without taking into account the objectives, financial situation or needs of a particular person. All financial information contained in this presentation must be read subject to, and in conjunction with, the information contained in any prospectus (whether in draft or final form) that is provided to you by LifeHealthcare. This presentation is not and does not form an offer, part of an offer, invitation or recommendation to subscribe for, or purchase any security or asset. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment. You must seek your own legal or other professional advice.

Reliance should not be placed on the information or opinions contained in this presentation. In particular, this presentation has not been verified. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the statements, estimates, opinions, conclusions and other information contained in this presentation. To the maximum extent permitted by law, UBS, Crescent Capital Partners, LifeHealthcare and their affiliates and related bodies corporate, and their respective officers, directors, employees and agents (relevant party), accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim any liability whatsoever (including, without limitation, any liability arising from fault or negligence) for any direct or indirect loss or damage howsoever arising from any use of this presentation or anything contained in or omitted from this presentation or otherwise arising in connection therewith.

You should be aware that any forecasts, projections or other forward looking statements in this presentation are subject to inherent known and unknown risks and uncertainties. Those risks and uncertainties include factors and risks specific to the business of LifeHealthcare as well as general economic conditions and conditions in the financial markets. Actual events or results may differ materially from the events, results, performances or achievements expressed or implied in any forecasts, projections or other forward looking statement and such deviations are both normal and to be expected.

No relevant party makes any representation or warranty (either express or implied) as to the accuracy of the analysis or likelihood of fulfilment of any forecasts, projections or other forward looking statement, or any events or results expressed or implied in any forecasts, projections or other forward looking statement, or guarantees the investment performance of the LifeHealthcare and you are cautioned not to place undue reliance on these statements. The forecasts, projections or other forward looking statements in this presentation reflect views held only as at the date of this presentation. Investors must make their own independent assessment of LifeHealthcare and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes including, without limitation, a full review of any prospectus or draft prospectus provided by LifeHealthcare to you.

You release UBS AG, Crescent Capital Partners, LifeHealthcare and their affiliates and related bodies corporate and any of their respective directors, officers, employees, representatives and advisers from any liability (including, without limitation, in respect of direct, indirect or consequential loss or damage or loss or damage arising by negligence) arising in relation to you relying on anything contained in or omitted from this presentation and irrevocably and unconditionally consent to submit to the jurisdiction of New South Wales, in respect of any disputes, actions, suits, or proceedings arising out of or relating to this presentation or the proposed purchase of shares in LifeHealthcare.

Each attendee of this presentation or any entity or person receiving this document represents, warrants and confirms that it understands and accepts the above conditions.



Introduction

Overview of LifeHealthcare

- LifeHealthcare is an ASX Listed specialised distributor of high-end medical devices to surgeons, hospitals and clinicians in Australia and New Zealand
 - Head office in Sydney with sales offices in Adelaide, Brisbane, Melbourne, Perth and Auckland
 - Focus on specialty clinical channels and products including Spine, Neurosurgery, Orthopaedics, Biologics, Cardiology, Capital and Neurophysiology

Value adding business model

- Combines the *flexibility to provide a comprehensive product portfolio* with the *scale* and reach to invest in growth and customer education
- Sustainable business model that benefits for both suppliers and customers
 - LifeHealthcare's leadership in clinical channels delivers market share for suppliers, reflected in long term exclusive agreements
 - Sales and support professionals with deep clinical expertise that is highly valued by surgeons

Strong financial track record

- · Track record of consistent and resilient growth
- Strong cash flow to assist in funding growth


Multiple growth opportunities


- Strong market growth driven by ageing population, supportive funding and demographic trends
- Numerous organic opportunities for LifeHealthcare to grow above market as its customer base matures and from new products and customers





Key Metrics and Historical Performance

LifeHealthcare has a strong track record of organic growth driven by market share gain through the implementation of its business model in focussed markets











Overview of LifeHealthcare

LifeHealthcare operates in high value segments of the Australasian medical devices market, specialising across a number of clinical channels


LifeHealthcare

	Implantable Devices	Non-implantable Devices	Capital Equipment
Description	 Devices surgically implanted to replace, support or enhance the existing biological structure of the body Examples include spine and joint prosthesis 	Devices used or consumed during surgical procedures Examples include surgical instruments, suction liners and bags	 Equipment that have an enduring nature and are used in either hospital operating theatre or outpatient clinical setting Examples include cardiac ultrasound machines, specialist spine tables and associated consumables
Clinical channels	Spine surgeryNeurosurgeryBariatricsInterventional Cardiology	Spine surgeryGeneral surgeryNeurosurgerySurgical instruments	CardiologySpine surgeryOrthopaedic surgeryNeurology
% of FY2013 revenue (\$76.9 m)	55%	15%	30%



LifeHealthcare's Business Model

Targeting channel leadership through leading products, represented by high quality sales team





LifeHealthcare's Sales People

LifeHealthcare employs 66 sales and clinical support professionals with deep clinical expertise in target practice areas and strong relationships with customers

Employee Profile

of people
7
66
23
8
33
137

- Due to the clinical nature of LifeHealthcare's products, sales representatives require deep knowledge and expertise in their clinical channels
- The educational background of many of LifeHealthcare's sales representatives is in Bachelor of Science or Nursing
- LifeHealthcare's remuneration structures are geared towards rewarding growth and performance against forecast

Case Study. Implantable Devices Sales Representative



- A LifeHealthcare sales representative typically attends the surgical procedure where a LifeHealthcare implant is used
- The sales representative or clinical support professional will:
 - ensure correct instruments and implants are ready for the case:
 - assist the nursing staff in the set up for the case;
 - help guide the scrub nurse through the procedure to ensure the smooth flow of the case for the surgeon;
 - provide technical advice on the products and related instruments to the surgeon during the procedure.
- Surgeons see this support as an integral part of the value proposition and is often, alongside patient outcomes, a key determining factor in product selection



Growth Strategy

Within 5 years, grow the business to circa \$200m in revenue through the three existing growth channels of Spine/Neuro, Orthopaedics and Cardiology and by developing a 4th or 5th new channel

Strategio Objectivo
Market Siz
Key Grow Strategy

Spine/Neuro

Leverage our strong existing market position.

- Continue to penetrate the market through new customers and new product introductions.
- Move from the current #3 position into #2 aiming for #1.

• ~ \$230m (Total)

- ~ \$60m (Deformity)
- ~ \$170m (Degenerative)

• Predominately organic growth strategy.

- Consolidate strong position in the Deformity market.
- Create leadership in motion preservation.
- Accelerate growth in Degenerative Spine through new product releases and investment in sales force.

Orthopedics

- Extend our presence in revision surgery into Primary Hip, Primary Knee and Sport Medicine, Extremities and Trauma (SET) markets.
- Implement the same business model adopted in Spine to grow market share.

~ \$1.0bn (Total)

- ~ \$650m (Hip & Knee)
- ~ \$350m (SET)

Initial focus on organic strategy in Primary Hips.

- Recruit 1st class sales team to implement new strategy.
- Identify acquisition opportunities in Hip/Knee and SET

Cardiology

- Leverage #1 position in Cardiac Ultrasound to enter the Interventional Cardiology space.
- Enter the Interventional Cardiology space first with Stents and the extend into other related products.
- ~ \$[\$500m] (Total)
- ~ \$100m (Interventional Cardiology)
- Enter Interventional Cardiology space through agreement with Biosensors.
- Build a high calibre sales team.
- Extend the product range into related products.
- Identify acquisitions for bolt-on opportunities.

New Channel(s)

- To add a 4th or 5th growth channel to the LifeHealthcare business.
- Target segments with similar characteristics to the existing three growth channels.
- Dental ~\$250m
- IVD ~ \$1.0bn
- Ophthalmology ~\$450m
- Imaging ~\$720m
- Identify acquisition targets with good existing product range and sales team
- Implement the LifeHealthcare business model to enhance and grow the business.
- Execute specific growth opportunities.



Pioneering Innovation

Click here for link to Mazor news video







> Leading through partnerships in health